MedPath

Comparative Effectiveness of Endoscopic Assessment of Gastroesophageal Reflux and Barretts Esophagus

Not Applicable
Completed
Conditions
Barrett's Esophagus
Interventions
Device: Sedated Endoscopy
Device: Transnasal Endoscopy
Registration Number
NCT01288612
Lead Sponsor
Mayo Clinic
Brief Summary

The hypothesis of this study was that the comparative effectiveness of unsedated transnasal endoscopy (uTNE) will be greater than sedated endoscopy (sEGD) in population screening for BE.

Detailed Description

Barrett's esophagus (BE), a well-known complication of Gastroesophageal Reflux (GER), is the strongest known precursor of esophageal adenocarcinoma. Thus, identifying effective screening approaches for the early detection of BE are highly desired. Current impediments to BE screening include 1) the inability to utilize sedated endoscopy (sEGD) effectively in populations and 2) current GER-based paradigms for detecting BE. Referral center studies demonstrate comparable accuracy between unsedated transnasal endoscopy (uTNE) and sEGD. However, patient acceptability and diagnostic yield with uTNE in general populations remain unknown.

Using the Rochester, Minnesota Epidemiology Project resources, random samples of Olmsted County residents were drawn, and those subjects were mailed validated gastrointestinal symptom questionnaires. These surveys allowed identification of a cohort of community subjects well characterized by the frequency of reflux symptoms. Eligible subjects who were greater than or equal to 50 years old, and who had no previous history of endoscopic evaluation and who were not known to have BE were randomized, stratified by age, sex, and reflux symptoms, and assigned to one of the 3 arms of the study. Subjects in each arm who met the eligibility criteria were initially sent generic invitation letters asking if they agreed to be contacted by phone in two weeks' time to inform them about a research study. If potential subjects explicitly declined to be contacted they were excluded from the study. Eligible subjects were contacted by telephone and only offered the endoscopy technique they had been randomized to. Subjects who accepted and signed an informed consent document were treated according to their randomized assignment and all 3 groups were followed up in the same manner.

Biopsies were taken from any endoscopically suspected BE and from the gastroesophageal junction and squamous mucosa in all subjects. The length of BE segment was defined using Prague criteria. All participants received a telephone call from the research coordinator 1 and 30 days after the procedure to complete validated tolerability scales and adverse events questionnaires.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
459
Inclusion Criteria
  • Olmsted county, Minnesota resident
  • Age 50 or older
  • Able to give informed consent
Read More
Exclusion Criteria
  • History of known Barretts Esophagus (BE) or endoscopy within the last 10 years
  • History of progressive dysphagia
  • Known Zenkers or epiphrenic diverticulum
  • History of recurrent epistaxis
  • Illnesses that impair ability to complete questionnaires (e.g. metastatic cancer, stroke, dementia)
  • Contraindication to esophageal biopsy (such as anticoagulation using warfarin or clopidogrel).
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Sedated EndoscopySedated EndoscopySedated esophagogastroduodenoscopy with biopsy
Transnasal Endoscopy at Mobile UnitTransnasal EndoscopyUnsedated transnasal endoscopy in mobile research van
Transnasal Endoscopy at Hospital UnitTransnasal EndoscopyUnsedated transnasal endoscopy at hospital unit.
Primary Outcome Measures
NameTimeMethod
Percentage of Subjects Who Agreed to Participated in the Esophageal AssessmentApproximately 2 weeks after invitation letter was sent

This outcome measure was defined as the proportion of subjects who agreed to undergo esophageal assessment in the three groups out of those who were eligible to be contacted for participation in screening.

Secondary Outcome Measures
NameTimeMethod
Rate of Complete EvaluationVisit 1

The rate of complete evaluation was defined as visualization of the whole esophagus and identification of landmarks: squamocolumnar junction, gastroesophageal junction (upper margin of gastric folds with stomach deflated), and the diaphragmatic hiatus. The categories of evaluation were classified as complete (all three landmarks identified), incomplete (some landmarks identified), or unsuccessful.

Rate of Successful IntubationVisit 1

The rate of successful intubation was defined as the ability to traverse the upper esophageal sphincter and visualize the esophageal mucosa and classified as successful or unsuccessful.

Rate of Acquisition of Biopsies From the EsophagusVisit 1
Mean Tolerability ScoresDay 1 after the procedure

Validated pain scales (where 0 is none and 10 is severe) were used to assess the degree of pain, choking, gagging, and anxiety experienced during the procedure. Overall tolerance was rated on a scale from 0 to 10, where 0 is good, and 10 is poor tolerance.

Mean Duration of ProcedureVisit 1

Duration of the procedure was defined as time from the beginning of the procedure (initiation of sedation or local anesthesia) to extubation.

Mean Time From Extubation to DischargeVisit 1

This outcome measures the recovery time after the procedure.

AcceptabilityDay 1 after the procedure

Acceptability was defined as the proportion of subjects willing to undergo the procedure again in the future.

Trial Locations

Locations (1)

Mayo Clinic in Rochester

🇺🇸

Rochester, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath